CLINICAL TRIALS PROFILE FOR SUSTIVA

505(b)(2) Clinical Trials for SUSTIVA

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Bristol-Myers Squibb	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Dupont Applied Biosciences	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Glaxo Wellcome	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Gilead Sciences	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.

All Clinical Trials for SUSTIVA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001758 ↗	Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1997-11-01	This study will continue to treat and collect safety and efficacy data on patients who participated in Glaxo-Wellcome's multi-center study on combination therapy with abacavir, amprenavir and efavirenz (A Phase II Study Evaluating the Safety and Antiviral Activity of Combination Therapy with 1592U89, 141W94 and DMP 266 (Sustiva) in HIV-1 Infected Subjects with Detectable [greater than 400 Copies/mL] HIV-1 Plasma RNA Despite Treatment with a Protease Inhibitor-Containing Regimen). HIV-infected patients 18 years of age and older who participated in the above study at the NIH site may be eligible for the current study. Participants will be followed every 3 months with a general health evaluation and laboratory tests. This is a NIH study, and information will not be provided to Glaxo Wellcome
NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Bristol-Myers Squibb	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Dupont Applied Biosciences	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Glaxo Wellcome	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.

Clinical Trial Conditions for SUSTIVA

Condition Name

Condition Name for SUSTIVA
Intervention	Trials
HIV Infections	36
HIV	11
HIV Infection	8
Healthy	5

Condition MeSH

Condition MeSH for SUSTIVA
Intervention	Trials
HIV Infections	47
Infections	9
Acquired Immunodeficiency Syndrome	9
Infection	8

Clinical Trial Locations for SUSTIVA

Trials by Country

Trials by Country for SUSTIVA
Location	Trials
United States	145
Spain	29
Canada	8
South Africa	6
Puerto Rico	6

Trials by US State

Trials by US State for SUSTIVA
Location	Trials
California	18
New York	11
District of Columbia	10
Texas	9
Florida	8

Clinical Trial Progress for SUSTIVA

Clinical Trial Phase

Clinical Trial Phase for SUSTIVA
Clinical Trial Phase	Trials
Phase 4	19
Phase 3	7
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for SUSTIVA
Clinical Trial Phase	Trials
Completed	55
Unknown status	4
Terminated	3

Clinical Trial Sponsors for SUSTIVA

Sponsor Name

Sponsor Name for SUSTIVA
Sponsor	Trials
Bristol-Myers Squibb	8
National Institute of Allergy and Infectious Diseases (NIAID)	6
Abbott	5

Sponsor Type

Sponsor Type for SUSTIVA
Sponsor	Trials
Other	76
Industry	44
NIH	15